ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anbenitamab

Also written as “KN026”, “KN026 combination” and “Recombinant Humanized Bispecific antibody against HER2,KN026”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageAnbenitamab: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 22, 201912 company-led studies, 7 open or runningLicense: Alphamab → CSPC (JMT-Bio), Aug 2021Next primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncologyits history only61 open or runningphase 2since Apr 22, 2019Aug 3, 2018none ahead
CSPC Pharmaceutical Group66 open or runningphase 3since Jun 14, 2022Jun 14, 2022Dec 16, 2026phase 3 · NCT06747338
  • Named in CSPC Pharmaceutical Group’s own pipeline as anbenitamab (KN026), phase 4, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named anbenitamabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KN026
  2. Aug 23, 2021CSPC (JMT-Bio) licensed it from AlphamabLicenseMainland China, in breast and gastric cancer · agreed · Alphamab Oncology (HKEX announcement)
  3. Jun 14, 2022First study: phase 3 study in Stomach NeoplasmsFirst studyNCT05427383 · 286 planned · China
  4. Apr 20, 2023Phase 3 study in Breast NeoplasmsNCT05838066 · 880 planned · China
  5. Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338 · 520 enrolled · China
  6. May 12, 2025Phase 2 study in HER2-positive Gastric CancerNCT06998771 · 153 planned
  7. Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerNCT07332533 · 490 planned
  8. Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerNCT07441460 · 1,800 planned · China

Ahead

  1. Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338
  2. Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerNCT06998771
  3. Jun 30, 2032Primary completion: phase 3 study in HER2-positive Gastric CancerNCT07332533
  4. Aug 7, 2034Primary completion: phase 3 study in Resectable HER2-positive Breast CancerNCT07441460

TargetBeta

“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HE…”NCIt, read by Claude
“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2;”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 6 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441460Resectable HER2-positive Breast Cancer · China3RecruitingAug 7, 20341,800
NCT07332533HER2-positive Gastric Cancer3Not yet recruitingJun 30, 2032490
NCT06998771HER2-positive Gastric Cancer2Not yet recruitingJun 30, 2028153
NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China3Active, not recruitingDec 16, 2026520
NCT05838066Breast Neoplasms · China3RecruitingJul 31, 2025880
NCT05427383Stomach Neoplasms · China3RecruitingNov 2025286

How it is read

Names in the registry

  • “KN026”, 7 entries
  • “KN026 combination”, 2 entries
  • “Recombinant Humanized Bispecific antibody against HER2,KN026”, 1 entry
  • “KN026 10 mg/kg QW”, 1 entry
  • “KN026 20 mg/kg Q2W”, 1 entry

Codes read as this program: KN026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.